MX2022007779A - Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos. - Google Patents

Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos.

Info

Publication number
MX2022007779A
MX2022007779A MX2022007779A MX2022007779A MX2022007779A MX 2022007779 A MX2022007779 A MX 2022007779A MX 2022007779 A MX2022007779 A MX 2022007779A MX 2022007779 A MX2022007779 A MX 2022007779A MX 2022007779 A MX2022007779 A MX 2022007779A
Authority
MX
Mexico
Prior art keywords
immune effector
effector cells
engineered
subject
treatment
Prior art date
Application number
MX2022007779A
Other languages
English (en)
Inventor
Ugur Sahin
Katharina Reinhard
Matthias Birtel
Veronika Jahndel
Petra Oehm
Benjamin Rengstl
Kristina Michel
Arne Billmeier
Nina Hayduk
Oliver Klein
Kathrin Kuna
Yasmina Ouchan
Original Assignee
Biontech Cell & Gene Therapies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Cell & Gene Therapies Gmbh filed Critical Biontech Cell & Gene Therapies Gmbh
Publication of MX2022007779A publication Critical patent/MX2022007779A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a métodos para mejorar la eficacia de terapias que involucran células efectoras inmunitarias tales como células T modificadas por ingeniería genética para expresar receptores de antígenos tales como receptores de células T (TCRs) o receptores de antígenos quiméricos (CARs). En el presente documento se demuestra que tales células efectoras inmunitarias modificadas por ingeniería de receptores de antígenos, incluso cuando se proporcionan a un sujeto en cantidades sub-terapéuticas, son extremadamente eficaces en el tratamiento de enfermedades cancerosas, incluso aquellas enfermedades cancerosas que se sabe que son difíciles de tratar con células efectoras inmunitarias modificadas por ingeniería de receptores de antígenos, tales como tumores sólidos o cánceres, si se proporciona al sujeto antígeno objetivo adicional para el receptor de antígeno. Las células efectoras inmunitarias pueden diseñarse ex vivo o in vitro y, posteriormente, las células efectoras inmunitarias pueden administrarse a un sujeto que necesite tratamiento, o las células efectoras inmunitarias pueden diseñarse in vivo en un sujeto que necesite tratamiento.
MX2022007779A 2019-12-23 2020-12-22 Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos. MX2022007779A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2019/086950 WO2021129927A1 (en) 2019-12-23 2019-12-23 Treatment with immune effector cells engineered to express an antigen receptor
PCT/EP2020/087623 WO2021130223A1 (en) 2019-12-23 2020-12-22 Treatment involving immune effector cells genetically modified to express antigen receptors

Publications (1)

Publication Number Publication Date
MX2022007779A true MX2022007779A (es) 2022-10-03

Family

ID=69726548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007779A MX2022007779A (es) 2019-12-23 2020-12-22 Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos.

Country Status (15)

Country Link
US (1) US20230000962A1 (es)
EP (1) EP4081247A1 (es)
JP (1) JP2023508653A (es)
KR (1) KR20220119613A (es)
CN (1) CN114901304A (es)
AR (1) AR120894A1 (es)
AU (1) AU2020414376A1 (es)
BR (1) BR112022010345A2 (es)
CA (1) CA3162601A1 (es)
CL (1) CL2022001715A1 (es)
CO (1) CO2022009086A2 (es)
CU (1) CU20220039A7 (es)
IL (1) IL294122A (es)
MX (1) MX2022007779A (es)
WO (2) WO2021129927A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3242106A1 (en) * 2021-12-09 2023-06-15 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2024046572A1 (en) * 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
PT2316852E (pt) 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
PL1729795T3 (pl) 2004-02-09 2016-08-31 Human Genome Sciences Inc Białka fuzyjne albuminy
US20070269422A1 (en) 2006-05-17 2007-11-22 Ablynx N.V. Serum albumin binding proteins with long half-lives
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
KR20100111283A (ko) 2007-12-27 2010-10-14 노파르티스 아게 개선된 피브로넥틴계 결합 분자 및 그들의 용도
EP2274331B1 (en) 2008-05-02 2013-11-06 Novartis AG Improved fibronectin-based binding molecules and uses thereof
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
KR20130056871A (ko) 2010-04-13 2013-05-30 브리스톨-마이어스 스큅 컴퍼니 Ｐｃｓｋ９에 결합하는 피브로넥틴 기반 스캐폴드 도메인 단백질
AU2012258087B2 (en) 2011-05-13 2017-07-20 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
AU2012311451B2 (en) 2011-09-23 2017-08-10 Universitat Stuttgart Serum half-life extension using immunoglobulin binding domains
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP6726656B2 (ja) * 2014-04-01 2020-07-22 バイオエヌテック セル アンド ジーン セラピーズ ゲーエムベーハーＢｉｏｎｔｅｃｈ Ｃｅｌｌ ＆ Ｇｅｎｅ Ｔｈｅｒａｐｉｅｓ Ｇｍｂｈ クローディン６特異的免疫受容体およびｔ細胞エピトープ
WO2016005004A1 (en) 2014-07-11 2016-01-14 Biontech Rna Pharmaceuticals Gmbh Stabilization of poly(a) sequence encoding dna sequences
MX2017005344A (es) * 2014-10-27 2017-08-15 Hutchinson Fred Cancer Res Composiciones y metodos para reforzar la eficacia de inmunoterapia celular adoptiva.
WO2016180467A1 (en) * 2015-05-11 2016-11-17 Biontech Cell & Gene Therapies Gmbh Enhancing the effect of car-engineered t cells by means of nucleic acid vaccination
WO2019067951A2 (en) * 2017-09-29 2019-04-04 Nantcell, Inc. CD1D AND TCR-NKT CELLS
CN113727720A (zh) * 2019-02-08 2021-11-30 生物技术细胞和基因治疗公司 用于治疗表达cldn6的癌症的嵌合抗原受体修饰的细胞

Also Published As

Publication number Publication date
WO2021129927A1 (en) 2021-07-01
JP2023508653A (ja) 2023-03-03
KR20220119613A (ko) 2022-08-30
CN114901304A (zh) 2022-08-12
CA3162601A1 (en) 2021-07-01
EP4081247A1 (en) 2022-11-02
BR112022010345A2 (pt) 2022-08-16
AU2020414376A1 (en) 2022-06-23
CO2022009086A2 (es) 2022-09-09
WO2021130223A1 (en) 2021-07-01
AR120894A1 (es) 2022-03-30
CL2022001715A1 (es) 2023-03-03
CU20220039A7 (es) 2023-01-16
IL294122A (en) 2022-08-01
US20230000962A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
PH12020551160A1 (en) Chimeric antigen receptors targeting cd70
MX2022008288A (es) Monocitos/macrofagos modificados que expresan receptores de antigeno quimerico y sus usos.
BR112021018442A2 (pt) Anticorpos multiespecíficos egfr x cd28
MX2019006598A (es) Celulas asesinas naturales modificadas geneticamente y sus usos.
MX2020009475A (es) Inmunoterapia con celulas car de anticuerpos biespecificos.
CL2020001898A1 (es) Tratamientos contra el cáncer de útero. (divisional solicitud 201802508)
MX2019008503A (es) Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
PH12020550242A1 (en) Multifunctional immune cell therapies
MX2019002474A (es) Composiciones de agente de unión de portador-ligando-1 de muerte programada y métodos de uso de las mismas para el tratamiento de cánceres.
WO2014008206A3 (en) DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
MX2018008106A (es) Terapias con celulas inmunoefectoras de una eficacia mejorada.
MX2017005106A (es) Metodos y composiciones para dosificacion en terapia celular adoptiva.
EA202190181A1 (ru) Композиции и способы для направленной иммунотерапии flt3, pd-1 и/или pd-l1
Rekers et al. The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
MX2021009357A (es) Dianas de genes de combinacion para mejorar la inmunoterapia.
MX2018012488A (es) Linfocitos t activados por bite ex vivo.
WO2011109400A3 (en) Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
MX350203B (es) Composiciones para tratar cáncer y usos de las mismas.
CL2022001715A1 (es) Tratamiento que involucra células efectoras inmunitarias modificadas genéticamente para expresar receptores de antígenos
MX2020007281A (es) Composiciones y métodos que se dirigen a cánceres que expresan cd99.
MX2020000686A (es) Composiciones y métodos para el direccionamiento de cánceres que expresan cd33.
MX2022003195A (es) Moleculas de union a pd-l1 que comprenden andamios de la subunidad a de la toxina shiga.
MX2022000016A (es) Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer.